Clinical Trial on HIPEC with Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)

Inclusion Criteria:

1. Histologically confirmed colon adenocarcinoma, except signet ring cell carcinomas (those with > 50% of the tumor composed of these cells, which comprise only 1% ofall colon adenocarcinomas).

2. Absence of previously treated or current extraperitoneal metastases, includingdistant lymphadenopathy (retroperitoneal, mediastinal, etc), liver metastases, orlung metastases (ruled out by PET-scan in case of doubt).

3. Synchronous or metachronous peritoneal metastasis of mild to moderate volume, with aPCI ≤ 20 (Appendix 2) (intraoperative confirmation).

4. Macroscopically complete surgical cytoreduction CCS-0 (intraoperative confirmation).

5. Treatment with perioperative systemic chemotherapy (SCT), before and/or aftersurgical procedure.

6. Age> 18 years.

7. Acceptable anesthetic/surgical risk: ASA 1-3 (Appendix 3), ECOG 0-1 (Appendix 4). Nosevere alterations in hematological, renal, cardiac, pulmonary or hepatic function (operable patients).

8. Information to the patient and signing of a study-specific informed consent.

Exclusion Criteria:

1. Peritoneal carcinomatosis of any other origin, particularly rectal cancer orappendicular adenocarcinoma, or signet ring cell colon cancer on histology.

2. No intraoperative confirmation of peritoneal disease (PCI 0). Likewise, cases ofperianastomotic (local) or lymph node (locoregional) recurrences will be excluded.

3. High volume peritoneal disease with a PCI> 20 (intraoperative evaluation).

4. Concurrent or previously treated extraperitoneal disease.

5. Disease progression during preoperative chemotherapy, if received.

6. Patients previously treated with HIPEC.

7. History of other cancers (except cutaneous basal cell carcinoma or cervix carcinomain situ) in the 5 years prior to entry into the study.

8. Patients included in another first-line clinical trial for the studied disease.

9. Pregnancy (or suspicion of it) or lactation period.

10. Emergency surgical intervention for obstruction or perforation of a primary tumourwith synchronous PM (although rescue and secondary CRS + HIPEC after emergencysurgery of the primary tumour are acceptable if inclusion criteria are fulfilled).

11. Persons deprived of liberty or under legal or administrative supervision.

12. Inability to understand the nature of the intervention, the risks, benefits,expected evolution and the need to undergo periodic medical examinations, either forgeographical, social or psychological reasons.